Design Therapeutics’ Friedreich’s Ataxia Data and Vincentage’s Obesity Results from China on May 19, 2026 Agonist China clinical improvement DT-216P2 frataxin frataxin protein Friedreich Ataxia Glucagon-Like Peptide 1 mFARS obesity trial Oral cavity Phase 3 RESTORE-FA RNA, Messenger VCT220 Vincentage Pharma Weight Loss +
Recent Biotech News: Gene Therapy Advances, Takeda Phase Success, and UK Cancer Funding on May 05, 2026 acquisitions cancer funding gene therapy RNA, Messenger Takeda UK +
BioNTech Founders Ugur Sahin and Özlem Türeci to Depart and Launch New mRNA Venture on March 11, 2026 BioNTech RNA, Messenger Spinout Ugur Sahin +
FDA Reverses Course on Moderna's mRNA Flu Vaccine Application After Initial Rejection on February 19, 2026 Approved Clinical Trials Moderna Reversal RNA, Messenger United States Food and Drug Administration Vaccines +
FDA Reverses Course and Agrees to Review Moderna's mRNA Flu Vaccine on February 18, 2026 Clinical Trials Moderna Reversal Review [Publication Type] RNA, Messenger United States Food and Drug Administration Vaccines +
BioNTech and UPenn Launch $50M Seed Fund for Early-Stage Biotechs on January 13, 2026 BioNTech biotech startups methionine RNA, Messenger seed fund UPenn +
BioNTech and UPenn Launch $50M Seed Fund for Early-Stage Biotechs on January 12, 2026 BioNTech biotech startups methionine RNA, Messenger seed fund UPenn +
BioNTech and UPenn Launch $50M Seed Fund for Early-Stage Biotechs on January 12, 2026 BioNTech biotech startups methionine RNA, Messenger seed fund UPenn +
Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector on October 06, 2025 advanced therapies Alternative Cells Clinical Trials commercialization Gene Modification gene therapy Industry meeting MESA partnerships payment Phoenix Arizona regulatory challenges RNA, Messenger Study models +
GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal on August 11, 2025 BioNTech COVID19 (disease) CureVac Influenza virus vaccine Pfizer RNA, Messenger royalties settlement SmithKline Beecham Vaccines +
BioNTech Acquires CureVac to Advance mRNA Cancer Therapies and End Patent Disputes on June 18, 2025 Acquisition BioNTech biotech merger COVID19 (disease) CureVac Immunotherapy for cancer Legal patent merger RNA, Messenger Vaccines +